All In Biotech

Drug Trial Radar · NCT06930352

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

Last checked: Nov 21, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jan 15, 2027

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Uma BorateAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kura Oncology, Inc.
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and/or aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and/or aspiration

  • CytarabineDrug

    Given cytarabine

  • Echocardiography TestProcedure

    Undergo ECHO

  • HydroxyureaDrug

    Given hydroxyurea

  • LeukapheresisProcedure

    Undergo leukapheresis

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Questionnaire AdministrationOther

    Ancillary studies

  • ZiftomenibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete remission (CR) plus CR/response with hematologic improvementTime frame: After 6 cycles of treatment (cycle length = 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.